argenx: Detailed Company Information & Corporate Profile
Summary
argenx, headquartered in Boston, Massachusetts, focuses on antibody‑based medicines for oncology and autoimmune diseases. The company develops therapies targeting rare conditions such as myasthenia gravis, pemphigus vulgaris, immune thrombocytopenia, acute myeloid leukemia, high‑risk myelodysplastic syndromes, and chronic inflammatory demyelinating polyneuropathy, with a strong emphasis on immunotherapy.
With a workforce of 1,000–5,000 employees, argenx was founded in 2008 and generates annual revenue between $1 billion and $5 billion. Its leadership includes Chuck Saunders (Global Head, Trademarks & Brand Protection), Staci Graber (Head of Employee Communications and Engagement), Kenneth Bachek (Head Clinical Site Agreements), Lisa Wright (Digital Technology Product Owner – Commercial Planning & Readiness), Daniel (Head, Medical Affairs & Evidence Generation Strategy and Planning), Rikki Allard (Senior Manager, Commercial FP&A), Jarred Kiel (Associate Director, Access and Reimbursement), David Grabke (Territory Business Manager), Tom Peddicord (Senior Director, Payer & HEOR MSLs and Immunology MSLs Lead), Starla Swaim (Director, Medical Science Liaison – Immunology (Rheumatology & Dermatology)), Babajide Bayo (Senior IT Consultant/ Leader), Deepika Cattry (Director, US Commercial HCP Marketing – Rheumatology), Casey Goodnough (Nurse Case Manager), Eiji (Territory Science Manager), Adam (Business Manager) and Priscilla Julian (Nurse Case Manager).
| argenx Website | argenx.com |
| Industries | |
| argenx Headquarters Address | 33 Arch Street, Boston, MA, 02110 US |
| Company Size | 1000-5000 employees |
| Specialities & Services | Oncology, Autoimmune diseases, Rare Diseases, Antibody based medicines, Immunotherapy, Myasthenia Gravis, Immunology, Pemphigus Vulgaris, Immune Thrombocytopenia, Acute Myeloid Leukemia , high-risk myelodysplastic syndromes, chronic inflammatory demyelinating polyneuropathy |
| Technologies | Fastly, jQuery, D3.js, Stimulus, Flask, Spring, ASP.NET, Laravel, Bootstrap, Material UI |
| Founded | 2008 |
| Estimated Annual Revenue | $1B - 5B |
| Updated: | 2026-09-24 |
Estimated Website Traffic
The chart shows a decline in traffic to the argenx.com website. In August, traffic decreased to 32150, compared to 36837 in the previous month. The highest traffic in 2026 was recorded in February, reaching 65585 visits.
Workforce Turnover
Number of employees switched from or switched to
Departmental sample breakdown
Length of Employment
argenx's workforce includes employees across a wide range of tenure levels.
4% have been with the company for less than 1 year29% have been with the company for 1 to 2 years23% have been with the company for 3 to 4 years28% have been with the company for 5 to 7 years8% have been with the company for 8 to 10 years8% have been with the company for more than 11 years
Companies Similar to argenx
argenx Corporate Information: FAQ
Data Privacy
GDPR COMPLIANT
SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.
CCPA COMPLIANT
SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.
